Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
Open Access
- 14 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 12
Abstract
The main systemic therapy for the management of hormone-sensitive prostate cancer (PC) is androgen deprivation therapy (ADT), with the use of long-acting luteinizing hormone releasing-hormone (LHRH) agonists considered the main form of ADT used in clinical practice to obtain castration in PC. The concomitant administration of antiandrogens for the first weeks could reduce the incidence of clinical effects related to the testosterone flare-up in the first injection of LHRH. On the contrary, Gonadotropin Rh (GnRH) antagonists produce a rapid decrease of testosterone levels without the initial flare-up, with degarelix commonly used in clinical practice to induce castration in PC patients. Even if no long-term data are reported in terms of survival to define a superiority of GnRH or LHRH, for oncological efficacy and PC control, data from randomized clinical trials and from real-life experiences, suggest a difference in cardiovascular risk of patients starting ADT. The age-related decline in testosterone levels may represent a factor connected to the increase of cardiovascular disease risk, however, the role of ADT in increasing CV events remains controversial. For these reasons, the aim of the paper is to synthesize the difference in cardiovascular risk between LHRH and degarelix in patients undergoing ADT. A difference in cardiovascular risk could be indeed an important parameter in the evaluation of these two forms of castration therapy. The Randomized trials analyzed in this paper sustain a possible protective role for degarelix versus LHRH agonists in reducing the rate of new CV events and interventions in the short-term period. On the contrary, real-word data are contradictory in different national experiences and are strongly conditioned by huge differences between the LHRH agonists group and the degarelix group.Keywords
This publication has 26 references indexed in Scilit:
- Association of Serum Testosterone and Luteinizing Hormone With Blood Pressure and Risk of Cardiovascular Disease in Middle‐Aged and Elderly MenJournal of the American Heart Association, 2021
- Ten-year cardiovascular risk among cancer survivors: The National Health and Nutrition Examination SurveyPLOS ONE, 2021
- Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate CancerJAMA Network Open, 2021
- Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational StudiesThe Journal of Sexual Medicine, 2018
- Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADTJournal of Clinical Oncology, 2015
- Testosterone: a metabolic hormone in health and diseaseJournal of Endocrinology, 2013
- Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?BJU International, 2012
- Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapyBJU International, 2009
- Is the flare phenomenon clinically significant?Urology, 2001
- Blood pressure and endogenous testosterone in menJournal Of Hypertension, 1988